After $-0.44 actual earnings per share reported by Enanta Pharmaceuticals Inc for the previous quarter, Wall Street now forecasts -540.91% EPS growth. Great West Life Assurance Can reported 0% in Enanta Pharmaceuticals Inc (NASDAQ:ENTA). Comerica Bancorporation stated it has 0% in Enanta Pharmaceuticals Inc (NASDAQ:ENTA). It engages in the research and development of molecule drugs for the treatment of infectious diseases such as hepatitis C virus, respiratory tract infections, intravenous and oral treatments. Envestnet Asset Mngmt has 0% invested in Enanta Pharmaceuticals Inc (NASDAQ:ENTA).
ENTA has been the subject of several other research reports.
Trading was light with 873 shares changing hands on Tuesday. The New Jersey-based Prudential Fincl has invested 0% in Enanta Pharmaceuticals Inc (NASDAQ:ENTA). J P Morgan Chase & Co restated an overweight rating and set a $38.00 price objective (up previously from $32.00) on shares of Enanta Pharmaceuticals in a research report on Wednesday, August 9th. On August 8 Baird kept the company rating at "Neutral" but moved up the price target from $27.00 to $36.00. The short interest to Enanta Pharmaceuticals Incorporated's float is 9.36%. Ameriprise Financial holds 0% of its portfolio in Enanta Pharmaceuticals Inc (NASDAQ:ENTA) for 116,475 shares. The corporation has a market cap of US$1.18 Billion. It is now trading at $48.23 which is marginally over the 50 day moving average which is $43.87 and quite a bit above the 200 day moving average of $36.40.
Traders are a little more bearish on shares of Enanta Pharmaceuticals, Inc. of late at least if you consider the change in short interest.
The stock increased 0.32% or $0.16 during the last trading session, reaching $48.38. Enanta Pharmaceuticals had a negative net margin of 51.85% and a negative return on equity of 7.74%. The company had revenue of $7.51 million during the quarter, compared to analyst estimates of $8.08 million. Next quarter's EPS is estimated at $0.17 and the next full year EPS is anticipated to be $-0.91. The business's revenue for the quarter was down 46.3% on a year-over-year basis.
COPYRIGHT VIOLATION NOTICE: This report was posted by TrueBlueTribune and is the sole property of of TrueBlueTribune.
The following firms have recently changed their position in ENTA. Dupont invested in 0.01% or 16,233 shares. At present, 0 analysts call it Sell, while 0 think it is Hold. Municipal Employees Retirement System of MI boosted its holdings in shares of Enanta Pharmaceuticals by 3.5% in the second quarter. Municipal Employees Retirement System of MI now owns 3,280 shares of the biotechnology company's stock worth $118,000 after buying an additional 110 shares during the period. It fall, as 12 investors sold Enanta Pharmaceuticals Inc shares while 42 reduced holdings. Short shares grew from 1,237,039 to 1,257,591 over that timeframe.
Lomas Capital Management Llc holds 2.83% of its portfolio in Manchester United PLC for 810,030 shares. Stonepine Capital Management, LLC added to its ownership by buying 307,166 shares an increase of 165.9% from 03/31/2017 to 06/30/2017. Finally, SG Americas Securities LLC boosted its holdings in shares of Enanta Pharmaceuticals by 5.8% in the second quarter. SG Americas Securities LLC now owns 4,354 shares of the biotechnology company's stock worth $157,000 after buying an additional 237 shares during the period. Institutional investors own 66.06% of the company's stock.